The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT07151079




Registration number
NCT07151079
Ethics application status
Date submitted
27/08/2025
Date registered
3/09/2025
Date last updated
11/09/2025

Titles & IDs
Public title
TAG TEAM - Trans Adolescent Group Therapy
Scientific title
Evaluation of Trans Adolescent Group ThErapy for Alleviating Minority Stress (TAG TEAM): a Randomised Controlled Trial
Secondary ID [1] 0 0
110355
Universal Trial Number (UTN)
Trial acronym
TAG TEAM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Minority Stress 0 0
Acceptability 0 0
Psychological Distress 0 0
Anxiety 0 0
Depression in Adolescence 0 0
Coping 0 0
Wellbeing 0 0
Pride 0 0
Internalised Stigma 0 0
Community Connection 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Anxiety

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
BEHAVIORAL - Trans Adolescent Group ThErapy for Alleviating Minority stress

Experimental: TAG TEAM Intervention Arm - In the intervention arm Trans Adolescent Group ThErapy for Alleviating Minority stress (TAG TEAM) will be delivered in groups of 8 participants (maximum) from the same stratum. Participants will be allocated to strata based on school year level (Grades 7-9 and 10-12). Participation will occur across a 5-month period for those in the intervention arm, including approximately 2-weeks for allocation to a condition, completion of the 6-week TAG TEAM program and follow-up questionnaires at 19 weeks.

No intervention: Waitlist Control - Those randomly allocated to the waitlist control arm from the same stratum will receive TAG TEAM after waiting a total of 19 weeks.


BEHAVIORAL: Trans Adolescent Group ThErapy for Alleviating Minority stress
The intervention, Trans Adolescent Group ThErapy for Alleviating Minority stress (TAG TEAM), is a group Cognitive Behavioural Therapy (CBT) program, originally developed using co-design methodology with trans and gender diverse young people. The 6 weekly, 2-hour session TAG TEAM program aims to improve mental health and wellbeing using evidence-based cognitive and behavioural strategies to target minority stressors discrimination and internalised stigma and facilitating community connection and pride. The intervention will be delivered by a psychologist facilitator and peer facilitator, who will both be trained and supervised by clinical psychologists, to groups of 8 participants from the same stratum.

Intervention code [1] 0 0
BEHAVIORAL
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Changes in level of psychological distress measured using the total score from the Depression Anxiety Stress Scales - Youth version (DASS-Y)
Timepoint [1] 0 0
Measured at baseline (week 0) and 6 weeks after enrolment.
Secondary outcome [1] 0 0
Changes in level of psychological distress measured using the total score from the Depression Anxiety Stress Scales - Youth version (DASS-Y)
Timepoint [1] 0 0
Measured at baseline (week 0) and 19 weeks after enrolment.
Secondary outcome [2] 0 0
Changes in level of anxiety measured using the Anxiety subscale of the Depression Anxiety Stress Scales - Youth version (DASS-Y)
Timepoint [2] 0 0
Measured at baseline (week 0), 6 weeks and 19 weeks after enrolment.
Secondary outcome [3] 0 0
Changes in level of depression measured using the Depression subscale of the Depression Anxiety Stress Scales - Youth version (DASS-Y)
Timepoint [3] 0 0
Measured at baseline (week 0), 6 weeks and 19 weeks.
Secondary outcome [4] 0 0
Changes in level of Stress measured using the Stress subscale of the Depression Anxiety Stress Scales - Youth version (DASS-Y)
Timepoint [4] 0 0
Measured at baseline (week 0), 6 weeks and 19 weeks.
Secondary outcome [5] 0 0
Changes in Coping as measured by the Brief Coping Orientation to Problem Experienced (Brief COPE) revised questionnaire
Timepoint [5] 0 0
Measured at baseline (week 0), 6 weeks and 19 weeks after enrolment.
Secondary outcome [6] 0 0
Changes in Wellbeing as measured by the World Health Organization-Five Well-Being Index (WHO-5)
Timepoint [6] 0 0
Measured at baseline (week 0), 6 weeks and 19 weeks after enrolment.
Secondary outcome [7] 0 0
Changes in response to the minority stressor of internalised stigma as measured by the Gender Minority Stress and Resilience Measure - Adolescent version (GMSR-A)
Timepoint [7] 0 0
Measured at baseline (week 0), 6 weeks and 19 weeks after enrolment.
Secondary outcome [8] 0 0
Changes in response to the minority stressor of Pride in Gender as measured by the Gender Minority Stress and Resilience Measure - Adolescent version (GMSR-A)
Timepoint [8] 0 0
Measured at baseline, 6 weeks and 19 weeks.
Secondary outcome [9] 0 0
Changes in response to the minority stressor of Community Connectedness as measured by the Gender Minority Stress and Resilience Measure - Adolescent version (GMSR-A)
Timepoint [9] 0 0
Measured at baseline (week 0), 6 weeks and 19 weeks after enrolment.

Eligibility
Key inclusion criteria
Participants will be enrolled into the RCT only if they meet all the inclusion criteria and none of the exclusion criteria.



* Identifies as trans, non-binary, or gender diverse
* Is between the ages of 12 and 17 years inclusive
* Has completed primary school at the time of enrolment into the study
* Has current psychological stress symptomology as determined by a score of moderate or above on the DASS-Y
* Provide informed consent: All participants and parent/legal guardians must be willing to give informed consent
Minimum age
12 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has current acute suicidal symptomology as determined by a combination of clinical judgement and the results of the Ask Suicide-Screening Questions (ASQ) suicide screening tool (e.g., answer yes to question 5) to determine the risk of suicide (has an active plan and/or intent to suicide) at time of screening interview
* Is actively having treatment with any other group psychological intervention at the time of enrolment into the study
* Is not proficient in English (as the group Cognitive behaviour therapy (CBT) program will be delivered in English and funds aren't available for interpreters)
* Previous participation in the feasibility trial
* Is currently enrolled in tertiary study (e.g., undergraduate university)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Murdoch Children's Research Institute - Parkville
Recruitment postcode(s) [1] 0 0
3052 - Parkville

Funding & Sponsors
Primary sponsor type
Other
Name
Murdoch Childrens Research Institute
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Timothy J Cronin, PhD
Address 0 0
Murdoch Childrens Research Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Timothy J Cronin, PhD
Address 0 0
Country 0 0
Phone 0 0
+61393456991
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Individual participant data that underlie the results reported in this article after de-identification, upon reasonable request.
When will data be available (start and end dates)?
Beginning 6 months following analysis and article publication, the previously described data will be available while it is being actively stored by the researchers i.e., 15 years.
Available to whom?
Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions for access.
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.